BTA-EG4

• Description :

  BTA-EG4 is a catalase-amyloid interaction inhibitor, which can significantly enhance the neurotoxicity of amyloid peptides in catalase-overexpressing neuronal cells, and can be used in the study of neurodegenerative diseases[1].

• UNSPSC :

  12352005

• Target :

  Amyloid-β; Reactive Oxygen Species (ROS)

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB

• Applications :

  Neuroscience-Neurodegeneration

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/bta-eg4.html

• Solubility :

  10 mM in DMSO

• Smiles :

  CC1=CC=C2N=C(C3=CC=C(NCCOCCOCCOCCO)C=C3)SC2=C1

• Molecular Formula :

  C22H28N2O4S

• Molecular Weight :

  416.53

• References & Citations :

  [1]Amrutha Chilumuri, et al. Benzothiazole Aniline Tetra (ethylene glycol) and 3-Amino-1,2,4-triazole Inhibit Neuroprotection against Amyloid Peptides by Catalase Overexpression in Vitro.Amrutha Chilumuri, Mark Odell, and Nathaniel G. N. Milton.ACS Chemical Neuroscience 2013 4 (11), 1501-1512.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [921193-28-4]